Company tracker
Development stages are assigned from publicly traceable evidence. Proposed launch dates are not used as evidence, and company statements are identified as such.
United Kingdom / Guatemala
Follicle rejuvenation
Autologous follicle-cell expansion and injection
The company says an early patient cohort has begun receiving cells expanded from banked follicle tissue. No registered protocol or public treatment results were located.
South Korea
Follicle rejuvenation
Autologous dermal papilla cell product EPI-001
ClinicalTrials.gov lists a 42-participant dose-escalation and placebo-controlled study that began in January 2026.
Japan
De novo follicle regeneration
Engineered follicular units using epithelial, dermal papilla and supporting cells
The de novo platform remains preclinical. A September 2026 non-binding European collaboration memorandum initially concerns an adjacent conditioned-medium programme and does not change this stage.
United States
De novo follicle regeneration
iPSC-derived engineered follicular units intended to create new follicles
The company describes engineered follicular units and has reported preclinical human-hair formation work; no recruiting human trial was located.
Canada / Japan
Follicle rejuvenation
Autologous dermal sheath cup cells
A 19-participant Phase I/II registry study is complete, and a separate Japanese dose-ranging study was published. The source page discusses further study plans.
Canada / United States
Adjacent: follicle-derived secretome
Autologous secreted factors produced from cultured follicle-derived cells
A 60-participant registered study is testing secretome injections. This is not cell transplantation or new-follicle engineering.
Inclusion is not endorsement. Developers can request factual corrections at editor@haircloning.info.
Professional use
Review a sample of the proposed professional monitoring brief, including evidence labels, change assessment and source history.